ASSET PURCHASE AGREEMENT BY AND AMONG VIVUS, INC. As Seller MEDA AB As Buyer AND With respect to Sections 2.1, 2.7(b), 2.15, 3.1(b), 3.2, 3.3, 3.10, 3.16 and 7.2, only VIVUS REAL ESTATE, LLC Dated as of October 1, 2010Asset Purchase Agreement • February 26th, 2013 • Vivus Inc • Pharmaceutical preparations • New York
ASSET PURCHASE AGREEMENT (this “Agreement”) entered into as of October 1, 2010 by and among MEDA AB, a corporation organized under the laws of Sweden (the “Buyer”), VIVUS, Inc., a corporation organized under the laws of the State of Delaware (“Seller”), and, with respect to Sections 2.1, 2.7(b), 2.15, 3.1(b), 3.2, 3.3, 3.10, 3.16 and 7.2 only, Vivus Real Estate, LLC, a New Jersey limited liability company (“Vivus Real Estate”, and collectively with Seller, the “Seller Parties”). Buyer, Seller and Vivus Real Estate are referred to individually as a “Party” and collectively herein as the “Parties.”
TRANSITION SERVICES AGREEMENTTransition Services Agreement • February 26th, 2013 • Vivus Inc • Pharmaceutical preparations • New York
THIS TRANSITION SERVICES AGREEMENT (this “Agreement”) is entered into as of November 5, 2010 (the “Effective Date”) by and between MEDA AB, a corporation organized under the laws of Sweden (“MEDA”), and VIVUS, Inc., a corporation organized under the laws of Delaware (“VIVUS”). MEDA and VIVUS may be referred to herein individually as a “Party” or collectively as the “Parties.”
AGREEMENTAgreement • February 26th, 2013 • Vivus Inc • Pharmaceutical preparations • California
This Agreement made as of this 28th day of December, 2000 (hereinafter referred to as “EFFECTIVE DATE”), between TANABE SEIYAKU CO., LTD., a Japanese corporation having its principal office at 2-10 Dosho-machi 3-chome, Chuo-ku, Osaka, Japan (hereinafter referred to as “TANABE”) and VIVUS, INC., a corporation having its principal office at 1172 Castro Street, Mountain View, CA 94040, USA (hereinafter referred to as “VIVUS”). TANABE and VIVUS are sometimes referred to herein individually as a “Party” or collectively as “Parties”.
SETTLEMENT AND MODIFICATION AGREEMENTTechnology Assignment Agreement • February 26th, 2013 • Vivus Inc • Pharmaceutical preparations • Delaware
THIS SETTLEMENT AND MODIFICATION AGREEMENT (the “Settlement Agreement”), effective as of the date upon which all parties have signed below (the “Effective Date”), is by and between ASIVI, LLC, a Delaware limited liability company, with offices at 1172 Castro Street, Mountain View, California 94040 (“ASIVI”), VIVUS, INC., a Delaware corporation with a principal place of business at 1172 Castro Street, Mountain View, California 94040 (“VI”), ANDROSOLUTIONS, INC., a Tennessee corporation with a principal place of business at Suite 309, 200 Fort Sanders West Blvd., Knoxville, TN 37922 (collectively with its Affiliates, “ASI”), and Gary W. Neal, M.D., a natural person residing at 4701 Guinn Road, Knoxville, TN 37931 (“GWN”).
ASSET PURCHASE AGREEMENT by and among K-V PHARMACEUTICAL COMPANY and VIVUS, INC. dated as of March 30, 2007Asset Purchase Agreement • February 26th, 2013 • Vivus Inc • Pharmaceutical preparations • Delaware
This Asset Purchase Agreement (this “Agreement”) is made and entered into as of March 30, 2007, by and among K-V Pharmaceutical Company, a Delaware corporation (the “Acquiror”), and Vivus, Inc., a Delaware corporation (the “Seller”).
